launch coverag alpha seri
outperform rate price target repres upsid
current stock price concert clinical-stag biotechnolog compani util deuterium-bas
chemistri order develop de-risk treatment improv pharmacokinet safeti profil
exist non-deuter drug histori clinic and/or commerci use thu far concert
focus power dce platform indic autoimmun central nervou system
diseas billion-dollar market opportun current pipelin also focus
program fda approv treatment alopecia areata aa phase ii alzheim
agit phase negative-symptom associ schizophrenia phase initi
includ wealth upcom catalyst across everi core program
potenti transform year concert host kol call wednesday
march discuss treatment landscap alopecia areata encourag dial
multipl catalyst repres asymmetr risk-reward investor
plenti shot goal look forward concert data read-out fulli
own program complet phase trial partner program anticip mileston
payment initi phase ii trial fully-own partner program lion
share valu concert model come alopecia areata aa
expect phase ii data third dose cohort mg bid
qd vs bid data also assum neg ptab decis concert on-going legal saga
give concert year exclus year gener
becom avail given billion market opportun moderate-sever aa patient would
strong candid inhibitor commerci window base case still
provid concert plenti valu price target outlook back
conserv assumpt despit excit concert prospect
apr aa ptab decis ipr challeng
 first phase trial data otsuka/avanir alzheim
 phase data readout schizophrenia
 initi food-effect trial healthi volunt aa
 vertex initi phase ii monotherapi trial cystic fibrosi
 phase iia data readout third dose cohort mg aa
 phase ii data readout qd vs bid studi begin open-label extens studi
 initi phase ii studi schizophrenia
 second phase trial data otsuka/avanir
 initi first pivot phase studi aa
year left
analyst certif disclosur pleas see page
posit best class potenti first market alopecia areata aa phase ii clear efficaci
safeti profil path drug dose regimen base phase iia interim data make stand jak inhibitor develop
diseas devast dermatolog disord suffer experi patchi hair loss typic scalp sever form complet
loss hair without bodi involv life-threaten aa neg impact qualiti life caus psychological/emot
distress extent similar eczema psoriasi around peopl us suffer diseas given time
patient sever hair loss scalp current fda-approv treatment aa
particular aa moderate-sever patient earli phase iia data demonstr patient mg bid dose achiev
rel reduct overal score baselin week statist signific compar particip
placebo particip mg bid dose cohort impress mg bid dose also show statist
signific versu placebo rel chang score baselin anticip posit result
concert report phase iia data final mg bid dose cohort potenti phase studi could begin dose regimen
well-defin outcom on-going phase ii trial
product partnership concert lead two potenti phase readout
potenti futur milestones/royalti concert grant exclus right avanir acquir otsuka
develop agreement verg success deuter formul dextromethorphan combin
low-dos quinidin treatment alzheim agit fda approv therapi avanir nuedexta combin
pill mg dextromethorphan dm mg quinidin often use off-label treat alzheim agit appli po
indic avanir expect complet two phase trial trial complet anticip result mileston
payment concert pool set-asid develop regulatori achiev treatment alzheim agit
approv concert could receiv sales-bas royalti addit mileston payment avail indic
model valuat
contribut valu concert worth includ model given d-serin parent drug histori use
phase asset consid high-risk due unknown safeti toler confid sinc parent compound
d-serin studi clinic academ set uncov academic-l studi d-serin use human
investig therapeut use treatment schizophrenia studi report efficaci d-serin schizophrenia limit report
dont anticip surpris regard safeti phase data read addit spoke
kol ran sever aforement d-serin trial believ rational program base pharmacolog proof
nmda receptor hypofunct hypothesi genet find alter glutamaterg transmiss rare variant schizophren patient
neurochem differ brain tissu potenti use adjunct therapi treat schizophrenia patient
us neg symptom given year sale ramp anti-psychot us probabl success launch
attribut current valuat program
concert pipelin focus therapi could benefit improv pharmacokinet profil exist rational
drug develop program safeti profil well-character deuterated-analog unlik wors advers event
parent molecul benefit deuter includ improv dose schedul qd vs bid smaller dose improv safeti
profil due fewer toxic metabolit improv efficaci due increas bioavail issu address
test concert dce platform involv strateg substitut heavier deuterium isotop place hydrogen molecul
concert attempt identifi molecul benefit deuter often alter quickli metabol half-lif
cmax preserv mechan action
concert variou partnership provid opportun mileston payment besid avanir concert on-going partnership
vertex celgen celg pharmaceut even found home non-
activ program sale processa over-the-counter pcsa cipla nse cipla keep eye vertex expect
initi phase ii trial cystic fibrosi could result mileston payment approv us
eu total model futur potenti mileston probability-adjust basi partnership repres potenti
non-dilut fund sharehold help soften expens on-going research develop concert core pipelin
kol call wednesday us wednesday march kol call alopecia areata featur dr brett king associ
professor dermatolog yale univers particip pleas use follow dial-in inform
initi coverag
outperform rate pt
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar
sector analys recommend base deep fundament analysi goal help
creat alpha investor long run
close march
offer investor asymmetr risk-reward profil multipl catalyst
play next month
demonstr interim phase ii top-line efficaci trial on-going potenti shot first market
approv alopecia areata aa billion market opportun approv therapi
mg bid cohort patient achiev rel reduct overal score baselin week vs
patient placebo cohort mg bid dose readout
believ neg impact on-going patent litig fulli price stock compani continu prepar larg patent estat
dce platform improv pk metabol exist therapi de-risk drug develop nce
 invest pipelin deuter asset offer potenti longer term upsid compani
non-dilut fund billion partnership asset sale offer upsid potenti
otsuka/avanir vertex partnership price base case upsid case model
manag team histori compani build drug develop found member vertex
year concert expect readout two phase ii studi inform design pivot
phase studi begin ii data two phase studi trigger potenti
mileston iii data phase studi potenti initi phase ii
concert market capit million enterpris valu million
arriv price target base dcf valuat model
assum wacc termin growth rate fulli dilut share million
assum probabl success alopecia areata probability-adjust us peak sale
model probabl success schizophrenia probability-adjust us sale
model probabl success alzheim agit probability-adjust us sale
base case conserv assum neg ptab outcom well termin growth platform valu ex-u sale
compani valuat ascrib alopecia areata cash balanc product revenu mileston
primari driver concert valuat model due belief jak inhibitor
effect treat moderate-sever alopecia areata high unmet need patient
concert posit chanc one first market
scenario analysi upsid base case downsid
po potenti launch annual cost
on-going peak penetr
po given prior data d-serin schizophrenia
po certain otsuka/avanir vertex mileston
po potenti launch annual cost
peak penetr year onset gener
po given prior data d-serin schizophrenia
po certain otsuka/avanir vertex mileston
po potenti launch annual cost
peak penetr year onset gener
po given phase statu
po otsuka/avanir vertex mileston
note scenario assum dilut on-going atm financ announc march
consid invest high-risk invest reason limit follow
clinic concert valuat depend upon success outcom clinic studi particularli aa schizophrenia
alzheim agit addit inher risk drug develop certain deuter compound may suscept
failur extent base compound other previous studi test progress develop
regulatori concert develop therapi area high unmet need receiv regulatori approv
market compani histori commerci success sale may ultim meet project third parti risk
includ market accept addit market entrant could potenti displac concert therapi
legal certain patent litig on-going may prevent concert pursu regulatori commerci plan
price wide rang price approv jak inhibitor market variou indic price remain uncertain
due competit market pressur well reimburs dynam
intellectu properti concert intellectu properti portfolio may suffici prevent competitor similar technolog
deuter compet marketplac
financ concert may need rais addit capit dilut financ fund clinic trial approv
launch compani incur signific loss sinc incept expect incur loss next year
first treat
patient
jak seen
jak inhibitor work treatment alopecia areata includ sever form
hair loss
jak inhibitor look safe aa patient otherwis healthi safeti profil jak
inhibitor popul compar safeti profil myelofibrosi
patient treat ruxolitinib
current cours treatment aa patient depend outcom patient
desir afford will toler
seen hair loss
despit acknowledg great efficaci jak inhibitor kol patient
abl receiv treatment jak inhibitor fda approv
time/burden seek payor approv high
model neg
current approv antipsychot medic work posit symptom neg
cognit symptom schizophrenia well manag medic
d-serin could effect monotherapi provid patient earli stage diseas
otherwis could use exist antipsychot adjunct therapi except
clozapin
prolong half-lif potenti fewer
observ nephrotox issu d-serin pre-clin research mous model
focus
multipl
dopamin antipsychot market flood drug differ mechan
effect posit neg symptom would excit medic commun
unlik one therapi work everyon like good proport
schizophren would respond medic like d-serin
higher dose d-serin mg/kg use previou clinic studi like need
order efficaci
kol previous use dose d-serin high mg/kg kol
expect see nephrotox human dose
nuedexta dextromethorphan/quinidin use off-label regularli treatment
alzheim agit side effect profil manag take effect quickli
fda approv first alzheim agit medic would big impact
approv peopl agit requir pharmacolog intervent
could receiv drug
pcp main prescrib popul approv drug would help prescrib
indic current nuedexta ssri anti-psychot use off-label
quinidin use anti-arrhythm affect cardiac rhythm physician rais
concern nuedexta even though dose quinidin low
dose quinidin even less would make prescrib comfort use
consult
case
po concert inter part review sinc atyp ptab consid rehear
origin deni petit regard patent
neg outcom concert still move forward clinic develop
without patent elig year market exclus base case model
posit outcom concert entitl patent protect upsid case
tabl content
alopecia areata
alzheim
addit asset non dilut
dcf model revenu
analyst certif disclosur research rate
concert lexington ma-bas clinical-stag biotechnolog compani focus use deuterium chemistri
platform expand use previous studi approv drug
program evalu nce regulatori perspect
concert program clinic develop demonstr improv pk metabol properti non-deuter counterpart
compani tend focu autoimmun diseas central nervou system disord
sever near term mileston includ readout two phase ii studi alopecia areata aa
two phase studi alzheim agit phase studi schizophrenia
market opportun billion everi clinic program develop
potenti expand jak inhibitor use relat dermatolog indic explor part scope report
strong manag team histori drug discoveri commerci vertex demonstr abil pivot
concert strateg plan face neg data prior program
current patent litig creat overhang stock impli po built
howev path forward even neg outcom concert provid potenti upsid
current stock price
expect neg pressur stock follow ptab decis april focu valuat price target
concert continu invest dollar use dce platform
may provid futur upsid platform valu model base case
manag histori compani build drug develop
co-found chairman bod
found scientist vice-president drug discoveri vertex drug approv hiv
hcv cf bod faculti mit impact
co-found longwood fund founder co-found sever
biotech includ sirtri acquir glaxosmithklin alnara
acquir verastem ovasci flexpharma
found employe vertex senior vice-president cbo
cfo crispr revo biolog vice-president
financ genzym renal endocrin busi
cso svp clinic
neurogen corp assist professor neurosci
vertex
leadership ceo roger tung
chairman richard aldrich sinc
incept dr tung experi
inventor multipl therapi led
strong pipelin concert
meet manag
team reveal deliber approach
portfolio priorit team
also demonstr abil
accumen pivot clinic
program need partnership
vertex out-licens processa
cipla program progress
compani eventu need make
histori compani
found dr roger tung richard aldrich
ipo rais million clinic program develop time spastic associ multipl sclerosi spinal cord injuri
phi complet diabet kidney diseas phii neurolog disord avanir collabor
sale cystic fibrosi asset vertex million cash plu million addit mileston fund pipelin near term
petit
sinc ipo
signific valu
pipelin howev
year
believ
concert portfolio includ mix program everi phase develop preclin phase
addit compani maintain disciplin approach divest non-cor asset partner certain
program gener non-dilut fund feed develop expens core asset
total potenti mileston non-dilut fund strateg
note exclud out-licens otcmkt pcsa million non-cash consider
actual potenti mileston tbd depressiveavanirupfront phase ii develop mileston commerci launch mileston includ first indic royalti /cystic fibrosisvertexsal approv reimburs agreement mileston studi mileston payment earlier phase dose nda mileston mileston addit licens program licens exercis fee expir apr mileston payment mileston payment mileston payment first program second exercis fee expir apr mileston mileston net sale mid-singl digit low doubl digit d-pirfenidonehuntington cnsauspexroyalti net sale low singl digit n/a diseaseschang control due teva acquisit ornarcolepsyjazzupfront first phase ii develop mileston mileston mileston net sale mid-singl digist low doubl digit total exist potenti total total total total total total march
catalyst rich year concert
ptab decis ipr challeng us patent
initi food-effect trial healthi volunt
vertex expect initi phase ii monotherapi trial
phase iia data readout third dose cohort mg
phase ii data readout mg qd vs mg bid studi
otsuka/avanir second phase trial decemb alzheim agit
concert approach drug discoveri strategi limit risk take approv drug alreadi evid support safe effect
limit guess game tradit drug discoveri strategi limit knowledg new chemic entiti fare dose human
substitut deuterium hydrogen subtl chang effect drug metabol long remain blood stream use
appropri translat benefici effect clinic
exactli deuterium isotop hydrogen
deuterium stabl isotop hydrogen natur abund earth hydrogen may recal hydrogen take first spot
period tabl resid spot proton nucleu deuterium also contain proton also contain neutron well
contribut molecular weight make deuterium heavier hydrogen result effect molecular properti drug
deuterium first detect nobel prize chemistri later award harold urey discoveri
deuter drug made
short answer way small-molecul therapeut deuter precursor use instead
howev drug typic deuter effici manner simpli perform reaction swap select
hydrogen complet activ pharmaceut ingredi api
instead deuter start materi use synthet process place precursor hydrogen atom
deuterium incorpor varieti way deuterium ad place atom hydrogen
 ad form new c-d bond
often deuter water deuterium oxid heavi water reli upon incorpor deuterium
take-away point util deuterium seem like simpl switch realiti usual cut
reaction step use gener final product
exampl reaction util
one mani way deuter precursor
use add deuterium
sajiki et al complet replac via pd/c-catalyz h/d exchang reaction org lett pp
deuterium effect drug
swap hydrogen deuterium slow enzymat reaction rate case
caus physic differ
twice heavi
carbon-deuterium c-d bond shorter carbon-hydrogen c-h bond result greater stabil
reduc vibrat energi compar mean energi requir c-d bond break
slow reaction rate
deuterium slow reaction rate metabol enzym gut
liver result larger proport parent drug remain
exampl deutetrabenazin fda approv
reduc dose compar non-deuter parent compound
deutetrabenazin also report fewer side-effect accord
statist comparison two drug
gant use deuterium drug discoveri leav label drug chem pp
pirali applic deuterium medicin chemistri chem accept
appli appropri deuterium slow metabol enzym
multitud
extens pharmacokinet
patient complianc
dose schedul
prevent slow format
prevent racem stereoisom
improv bioavail
clinic preced deuterium therapeut
substitut deuterium hydrogen order improv properti drug new concept
appli technolog limit particular therapeut area limit particular chemic structur
howev deuter drug ever fda approv deutetrabenazin teva
acquir teva
relat patent public clinic trial initi
prevent stereoisom interconvers
deuter therapeut activ clinic trial
origin molecul parent
origin molecul parent
prevent stereoisom interconvers
pharmacokinet profil reduct
pharmacokinet profil reduct
spotlight effect deuter ivacaftor vs d-ivacaftor
ivacaftor market kalydeco vertex treatment cystic fibrosi
develop concert vertex purchas asset concert
ivacaftor current dose mg twice/day desir daili dose reliev pill burden cf patient
harbeson et al alter metabol profil drug precis deuter pharmacol ther pp
spotlight effect deuter ivacaftor vs d-ivacaftor
clinic studi ivacaftor mg hour half-lif vs mg hour half-lif
preclin studi abl withstand metabol liver enzym longer
preclin studi slow product drug metabolit human liver cell factor
vitro half-lif ivacaftor subject
degrad human liver
vitro format ivacaftor
metabolit human liver cell
harbeson et al alter metabol profil drug precis deuter pharmacol ther pp
spotlight effect deuter ivacaftor vs d-ivacaftor
rat increas hr increas cmax vs ivacaftor
dog increas hr increas cmax vs ivacaftor
introduct deuterium impact drug metabol larg impact challeng determin without preclin research
effect deuterium easili predict clinic trial necessari show deuterium abl differenti analog parent compound
vivo plasma concentr male
vivo plasma concentr male
harbeson et al alter metabol profil drug precis deuter pharmacol ther pp
alopecia areata
concert lead program alopecia areata
concert advanc wholly-own program develop phase ii treatment
alopecia areata aa therapeut oral select inhibitor develop concert
deuterium-modifi analog ruxolitinib current approv indic
investig columbia uncov gene underli aa includ act home
beacon cytotox cell hair follicl investig mous model patient cell
confirm role cell aa fda-approv jak inhibitor found block immun
nov concert announc interim phase iia data week result demonstr
patient mg bid dose reduct score rel baselin statist signific
compar placebo data mg bid cohort expect phase ii qd vs
bid studi readout potenti phase could begin earli
alopecia areata affect patient us patient sever diseas
scalp hair loss would justifi treatment oral jak inhibitor approv therapi
aa specif patient moderate-sever diseas multipl program clinic develop
could share market billion indic
potenti one first fda-approv oral treatment alopecia areata patient moderate-sever diseas
deuterium-modifi analog ruxolitinib
select inhibit janu kinas known
act suppress ifn- stimul format
on-going clinic develop includ two phase ii trial whose result
inform dose regimen studi design potenti phase pivot
studi begin
program breakthrough design statu fda
ruxolitinib commerci avail name jakafi us
treatment myelofibrosi polycythemia vera
jakafi previous use treat alopecia areata off-label investigator-
sponsor clinic trial columbia univers
promot hair growth individu moder sever diseas
increas therapeut window ruxolitinib favor safeti efficaci
octa-deuter analog ruxolitinib
argu analog obviou despit differ pk profil
clearanc auc vitro result show differenti metabol
stabil increas clinic respons given dose increas
essenti red blood cell
product also use jak/stat pathway result jak
inhibitor may also suppress red blood cell product caus anemia
occur patient take jakafi cmax
lower risk
concert patent owner preliminari respons ptab
confluenc circumst led creation
human diseas
high
exist approv
jak inhibitor
indic prove thesi
clinic set
jak janu kinas famili tyrosin kinas commun ligand
signal outsid cell nucleu via cytokin receptor
receptor activ caus jak phosphoryl transcript factor
known stat initi jak-stat signal pathway
activ stat transloc nucleu bind specif gene
promot regul prolifer differenti
four jak famili member similar
domain ferm domain
mediat signal ifn- receptor
transduc signal singl chain cytokin receptor
famili ifn- receptor
associ receptor -chain
associ
also interconnect
mapk/erk pathway via domain
samadi et al janu kinas jak inhibitor
treatment skin hair disord review literatur journal
mous model show lymphocyt necessari induc aa
mous model spontan develop alopecia recapitul mani patholog featur human aa
lesion skin biopsi show cell infiltr epitheli layer hair follicl overexpress
analog observ skin biopsi human aa
cell mast cell also present smaller number
therapeut antibody-medi blockad haploinsuffici ifn- prevent aa graft mice reduc
cell skin dermal ifn respons mous model aa antibodi alon revers establish aa mice
frequenc box area cell skin lymph node alopec mice versu ungraft mice
left dermal sheath cell grown hair follicl right dose-depend specif cell lysi induc
cell isol aa mice cutan lymph node presenc block antibodi
isotyp control hair loss mice inject subcutan total lymph node ln cell cell
alon cell lymph node cell deplet mice per group fisher exact test
xing et al alopecia areata driven cytotox lymphocyt revers jak inhibit med
columbia gwa pilot studi demonstr pathway role jak
genome-wid associ studi gwa identifi ligand target killer cell
inflammatori infiltr near hair follicl aa lesion human mous model aa
suscept loci includ eo gene involv regul activation/prolifer treg cell
lead product ifn- effector cytotox cell signal jak-sign transduc activ transcript
stat pathway also upregul sever -chain cytokin promot activ surviv cell
columbia team test tofacitinib ruxolitinib origin approv rheumatoid arthriti ra myelofibrosi mous model aa
prevent revers aa model earli week full regrowth week new hair persist sever month
decreas inflammatori signatur diminish
pilot open label trial patient moder sever aa
hair loss use oral ruxolitinib show efficaci
patient signific hair regrowth week
includ patient near-complet regrowth within month
reduct attack cell
chang gene express profil show higher keratin lower
ifn inflammatori signatur
success inhibit killer cell involv pathogenesi
provid rational expand clinic trial includ jak
inhibitor larger patient cohort
hair regrowth treatment aa patient
origin pilot studi columbia
sourc clinicaltri gov xing et al
janu kinas jak inhibitor treatment skin hair disord
competit landscap dermatolog includ multipl player variou type jak inhibitor differenti efficaci
launch/pric dynam key determin futur market share
jak/stat inhibitor approv clinic develop approv includ
jakafi ruxolitinib phosphat inhibitor myelofibrosi mf polycythemia vera pv
olumi baricitinib inhibitor licens rheumatoid arthriti ra also clinic poc aa
xeljanz tofacitinib citrat inhibitor ra ulcer coliti uc psoriat arthriti pa
count jak/stat inhibitor clinic studi treat dermatolog diseas includ psoriasi atop dermat
alopecia areata hidraden suppurativa dermatomyos vitiligo
within aa four main competitor jak inhibitor still explor dose although concert confirm
recent earn call mg bid dose highest dose intend pursu
data mg cohort phii qd vs bid dose data
potenti pivot phiii
topic
data phii dose rang trial data phii dose rang trial
dose rang studi sever patient fulli enrol
global pivot phiii use arm variou induction/mainten
dose schedul start estim complet
adapt phii/iii studi use high low dose start
estim complet interim data apr
sourc biomedtrack compani websit clinicaltri gov lifesci capit
address advers event jak inhibitor
jak inhibitor use treat indic exhibit sae seen aa patient thu far
jakafi indic treat myelofibrosi polycythemia vera pv
myelofibrosi dose depend platelet count mg bid pv mg bid
seriou advers reaction includ thrombocytopenia anemia one patient discontinu use
phase studi neutropenia patient phase studi reduc stop jakafi
treatment risk infect
number jak inhibitor treat moder sever rheumatoid arthriti exhibit
nyse upadacitinib seek approv ra phase trial result
hemorrhag stroke death pulmonari embol patient pre-exist risk factor
nyse olumi baricitinib black box warn seriou infect lymphoma
thrombosi patient
immunosuppress methotrex corticosteroid lower dose mg qd
approv reject fda character safeti
develop seriou
infect
recent nyse xeljanz tofacitinib warn issu fda februari post-
market safeti trial show increas occurr blood clot lung death patient
higher mg bid dose combin methotrex patient move mg bid
dose studi enrol ra patient year old least one cardiovascular risk factor
thu far gilead/galapago inhibitor filgotinib may safeti benefit
phase studi treat ra crohn diseas ulcer coliti aa
sourc jakafi prescrib label
aa commonli present discret patch alopecia scalp although hair-bear area may also affect
sever case patient may experi loss scalp bodi hair visibl manifest diseas neg impact
qualiti life particularli social function psychological/emot distress extent similar eczema
psoriasi aa simpli cosmet problem rather medic disord detriment impact patient
preval autoimmun diseas affect million peopl us preval
character transient non-scar hair loss preserv hair follicl typic relaps remit
histor defin patchi well-defin patch loss scalp universali diffus loss scalp totali bodi hair
clinic relev definit patient physician defin moder diseas hair loss sever aa scalp
hair loss without bodi involv
diseas often extend beyond hair follicl includ nail pit trachyonychia aa patient
caus collaps immun privileg hair follicl subsequ autoimmun attack cytotox lymphocyt
skin biopsi show lymphocyt infiltr around bulb lower part hair follicl anagen hair growth phase
peribulbar inflamm associ dystroph chang anagen follicl stimul prematur transit anagen follicl
non-prolif catagen telogen phase
impact qualiti life compar psoriasi substanti psychosoci burden
strong associ aa autoimmun diseas thyroid diseas patient vitiligo psoriasi lupu
rheumatoid arthriti aa also increas risk atop dermat allerg rhiniti asthma
korta et al alopecia areata medic diseas dermatol
exampl clinic manifest alopecia areata
patch alopecia areata show
exclam point hair slight
universali ophiasi pattern
alopecia areata spare white
hair alopecia areata nail
pit longitudin striation
trachyonychia associ
natur histori alopecia areata
clinic examin suffici diagnos aa may resolv moder case recur case
progress sever form alopecia totali alopecia universali
smooth circular discret area complet hair loss develop period week short hair broken millimet
skin surfac exclam point hair possibl found edg expand patch occasion pruritu burn sensat may
preced loss hair
alopecia commonli occur scalp may found hair-bear area men involv beard preced scalp
hair loss case usual within month white hair initi may spare lead appear rapid gray
cours diseas
symptom typic begin age
patient limit patchi hair loss recov within month although almost experi multipl episod diseas
aa may persist year case hair growth never recov
patient progress alopecia totali alopecia universali
aa polygen diseas includ innat acquir immun
genome-wid associ studi gwa patient nation
alopecia areata registri us implic innat
identifi singl nucleotid polymorph associ aa
case control includ
gene control activ prolifer regulatori cell
eo also known ikaro famili zinc finger
region contain gene express hair follicl
cycl develop
encod activ ligand natur killer cell receptor
previous implic autoimmun diseas
manhattan plot joint analysi discoveri
replic gwa eight genom region contain
exceed genome-wid signific threshold
studi alopecia areata implic innat adapt
gwa demonstr share pathway autoimmun diseas ii identifi novel diseas mechan
highli express lesion scalp aa patient upregul hair follicl dermal sheath activ diseas
treatment depend sever outcom vari wide cur therapi
first intralesion topic
corticosteroid triamcinolon
inject topic betamethason
best candid scalp hair loss
new growth possibl within week
treatment repeat everi week
necessari month gener
efficaci near complet
complet regrowth
immunotherapi see anthralin
anthralin limit evid efficaci
diphenylcyclopropenon
dpcp also corticosteroid therapi
strateg site frontal hairlin
patient complet hair
regrowth sign growth month
relaps common patient
depend mainten therapi
local skin atrophi frequent also
telangiectasia spider vein
irrit reaction erythema
scale expect rins
mild dermat common also sever
vitiligo dyschromia dpcp
potenti synthet precursor
mutagen ame assay also
unknown toxicolog profil chronic
reproduct teratogen
azathioprin jak inhibitor topic
oral methotrex sulfasalazin
suppress patient
tofacitinib increas risk infect
treatment algorithm manag alopecia areata
epidemiolog market size sever aa
assum diseas preval us patient note elig popul oral jak
inhibitor sever patient aa patient
global preval million peopl alopecia totali universali
lifetim risk aa estim regardless gender ethnic
frequent cite report mayo clinic nation institut show overal incid
aa per person-year lifetim risk
typic affect patient year age seek treatment age
patient posit famili histori
patient persistent/patchi aa patient progress totali
physician prescrib label usag jak inhibitor aa
anecdot kol treat primarili patient sever diseas prescrib xeljanz major
insur approv patient remain either util pfizer patient
assist program pay pocket kol also prescrib jakafi small hand patient due
differ cost jakafi vs xeljanz insur approv jakafi
patient
patient sever diseas desper enough effect treatment travel abroad
obtain one two jak inhibitor treat aa
sever aa
risk alopecia areata estim percent
safavi kh et al incid alopecia areata
olmst counti minnesota
macdonald et al guidelin
manag alopecia areata brit derm
demograph
patient studi
control trial adult patient
entri criteria least hair loss
measur sever alopecia
three dose
mg twice daili placebo week
mg cohort complet
mg cohort on-going data
expect
reduct week
baselin
respond week
patient mg bid arm achiev primari
endpoint patient random first two cohort
result mg bid dose statist signific
comparison mg bid dose cohort
placebo
mg bid dose potenti move phase
efficaci dose howev compani await
data third cohort
announc
per kol higher dose jak inhibitor produc
stronger effect aa patient must balanc
notabl respond mg bid dose cohort
evenli distribut among patient patchi aa
sever form
alopecia totali alopecia
universali distribut potenti implic
target popul commerci use model
sever patient case moder patient repres
big upsid penetr subgroup
kol discuss indic jak
inhibitor would requir chronic therapi
maintain effect long term
signific effect vs placebo week
week
onset
pf-
cours
treatment start induct phase
dose respect
mainten dose
confirm kol
advis upon similar induct
phase regimen also confirm
dilig
interest long
term outcom patient
respond visit
mg bid dose show statist
signific chang baselin
per kol higher dose jak tend
lead greater effect thu also expect
see statsig patient improv
potenti third dose cohort
import determin studi design
improv
clinic meaning patient
kol suggest therapi improv
criteria
like gain fda
kol also confirm patient outlook
want gain much hair back possibl
phase iia advers event patient top-line data
seriou report grade hematolog event distribut equal across placebo group
base kol convers would expect seriou advers event otherwis healthi aa patient
random multi-cent studi evalu efficaci toler qd vs bid dose adult patient
chronic moderate-to sever aa
entri criteria least hair loss measur sever alopecia tool
definit diagnosi aa current episod last least month exceed year
parallel open-label studi evalu mg qd dose regimen vs mg bid dose regimen week
primari endpoint rel chang sever alopecia tool score dose regimen week
secondari endpoint number particip week
march concert announc initi studi intend inform optim dose regimen
data readout expect patient complet week treatment elig enrol open label
extens studi
clinicaltri gov compani press releas march
insight jak inhibitor aad
recent attend american academi dermatolog aad meet held washington march
attend symposium jak inhibitor dermatolog feel confid jak inhibitor
safe effect alopecia areata patient
great excit use jak sever dermatolog indic includ alopecia areata vitiligo atop dermat
psoriasi name
tofacitinib common jak inhibitor use off-label dermatologist main reason due reimburs issu
cost annual cost tofacitinib annual cost ruxolitinib
dermatologist report patient travel outsid us order access drug insur cover
patient will go great length effect treatment
dermatologist present symposium express confid jak inhibitor safe effect alopecia areata
dr brittani craiglow pediatr dermatologist publish sever paper use oral topic formul tofacitinib ruxolitinib
treatment alopecia areata use tofacitinib patient young year old long month durat
report jak gener well toler patient treat common upper respiratori infect acn weight gain
also note patient suffer diseas year neg predictor respons jak therapi respons one
site hair growth scalp predict respons anoth site eyebrow
dr jerri shapiro hair scalp special dermatologist nyu langon health report use mg tofacitinib plu intralesion
corticosteroid alopecia areata patient greater hair loss
also note within month discontinu jak treatment loss hair growth often observ dermatologist still figur
long-term treatment alopecia areata look like jak inhibitor pose question kol believ chronic therapi
requir maintain effect sinc diseas genet compon cure jak inhibitor
recent data competitor lead us believ best-in-class
primari efficaci
endpoint improv hair regrowth scalp rel baselin
week jak inhibitor placebo-adjust mean ci
chang baselin score week point
point
patient baselin mean score
earli onset treatment week see pictur attribut
high induct phase dose regimen
note chose display placebo group graph
data-point
clear differenti patient respons depend durat diseas
believ clinic meaning endpoint would concert
studi least reduct baselin score pfizer
endpoint mean chang score baselin per kol
discuss reduct would good score reach
aclari phase ii studi show respons patient eyebrow
aa patient totalis/universali chang score
disclos readout expect patchi aa
topic oral help
us compar program
present aad march
associ professor
preval alopecia areata
kol reiter preval diseas appear
particular demograph like diseas
us kol reason million peopl us suffer alopecia areata
case like mild moder less hair loss
sever hair loss
special difficult
research focus
discoveri novel
areata vitiligo atop
sever
past year
use jak inhibitor alopecia areata
whole concept use jak inhibitor come form mous model alopecia areata
geneticist angela cristiano columbia immunologist raphael clyne
genet angela done look peopl registri
genet show gene activ mani patient carri strong interferon gamma signatur
gave way immunolog studi mous model pathway jak identifi
mous model diseas mice treat jak inhibitor xeljanz tofacitinib jakafi
ruxolitinib regrew hair awar scientif abstract back
thought arent use alopecia alway true mous model diseas
case mous model replic diseas well blown hundr patient jak
current jak inhibitor target specif
kol relay sentiment within medic commun jak-specif inhibitor desir
jak inhibitor may provid specif thu less off-target effect
percept improv safeti efficaci kol necessarili believ factual true
im unawar data say jak better jak exampl recent data nyse
phase iia suggest jak inhibitor better jak knowledg that data exist
world suggest one better
kol caution dose alway consid directli compar safety/efficaci variou jak comparison one
jak anoth imposs make never equival dose differ therapi data doesnt
exist data show good therefor jak inhibitor across spectrum go effect
safeti jak inhibitor
within context dermatolog kol reiter jak inhibitor look safe kol caution look
safeti profil jakafi ruxolitinib drug use patient myelofibrosi peopl sick oppos
patient alopecia areata besid hair loss usual otherwis healthi peopl safeti profil ruxolitinib
myelofibrosi use guidelin expect safeti profil alopecia areata patient
would person right steer peopl toward inhibitor year-old child buy somewher
world worri insur approv would use target immun cell
least petri dish
stand reason may immunosuppress mayb point distinct
dermatologist conserv anybodi present hypothet safeti equal efficaci youd pick one
concert phase ii program
think awesom cool slam dunk mind short realli surpris safeti signal emerg go win
race far earli data earli data concert earli data concert show
peopl succeed
compar phase ii data concert phase iia data kol summar roughli patient near
complet hair regrowth studi concert achiev well studi mg bid kol specul
increas dose mg bid concert might abl achiev patient complet hair regrowth
overal think data that present show theyll concert better cours also olumi
baricitinib nyse know look like aclari look like
clinic endpoint fda patient consid success alopecia treatment
within context pfizer phase data readout kol anticip report score patient achiev
chang score baselin howev kol caution achiev hair regrowth might sound like success
fda ultim patient may consid one conceptu hair re-growth would still need wig
kol caution bar success real life alopecia areata patient like higher bar set earli clinic
trial primari efficaci endpoint one thing want see percentag patient achiev
improv baselin assuredli none get fda approv anyth less improv baselin
skin hair care
gener
pediatr
oper
practic focu
hair scalp diseas
nation educ
american academi
practic
high-volum practic includ physician physician assist
clinic see patient come hair loss
total practic includ alopecia areata patient common clinic
preval alopecia areata
current treatment alopecia areata
mild moder patient less hair loss treatment includ topic steroid
believ preval estim lot peopl diagnos
inject steroid affect area
sever patient hair loss topic immunotherapi use includ anthralin
dpcp diphenylcyclopropenon squaric acid methotrex shed occur
ultim cours treatment depend patient afford toler
efficaci perhap topic peopl dont like put stuff hair
patient dont even want tri rogain minoxidil put anyth
scalp men would rather pill dont want topic everi day
concern safeti prefer topic inject pill prefer pill
pill cream probabl
patient satisfact current treatment
kol note lot unmet need hair loss cost treatment big issu sinc insur view
cosmet issu life-threaten diseas
kol note qualiti life patient poor sever diseas
challeng use jak inhibitor
despit larg volum alopecia areata patient current receiv jak inhibitor cours treatment due
difficulti insur compani cover drug
difficult labor love write letter dont get paid that difficult larg volum
person experi patient abl get efficaci great especi patient hair
loss month peopl go bald complet head hair practic coupl patient sinc
fda approv work compani get compassion use care
jak inhibitor would use approv
would offer offer buffet option let decid base risks/benefit risk take
collabor approach high amount patient would opt jak sinc frustrat dont option high
would opt even risk possibl sinc prefer stay natur lower hair loss involv would less like
patient would view clinic meaning alopecia areata treatment
peopl get hair want back didnt want back start regrow hair regrowth might
meaning want even
alopecia areata revenu assumpt sale po
epidemiolog estim cumul lifetim incid preval use kol estim aa patient
target patient popul assum patient moderate-sever diseas hair loss patient would elig jak
inhibitor base desire/ patient would respond jak inhibitor contempl dose
price label usag discuss kol treat aa larg driven price annual cost therapi xeljanz vs
jakafi addit mani aa patient obtain treatment abroad approv insur conserv model price
olumi per year sinc expect dose need chronic maintain efficaci long term ii insur may view aa
debilit approv indic rheumatoid arthriti psoriat arthriti myelofibrosi
patent exclus estim year patent exclus year gener becom avail also assum royalti mitig legal action
sourc frick miteva epidemiolog burden alopecia areata systemat review clinic cosmet investig dermatolog
revenu alopecia us popul patient total aa patient sever hair loss sever patient patient elig jak inhibitor patient penetr cost therapi increas complianc sale exclud royalti payment us sale adjust us net sale compani report lifesci capit estim march
schizophrenia
overview schizophrenia
concert phase asset treatment schizophrenia deuter version natur occur
amino acid d-serin unlik concert program never approv drug howev d-serin use
extens trial academic/clin set treat schizophrenia sinc
benefit
evid suggest nmda receptor function reduc schizophrenia level d-serin also reduc prior
clinic evid support treatment d-serin help allevi symptom
use d-serin therapeut limit due fear
d-serin caus increas aminoaciduria glucosuria proteinuria well necrosi proxim renal tubul rat
deuter d-serin potenti prevent issu due slower rate metabol breakdown
current phase single-ascend dose trial top-lin data expect
schizophrenia chronic psychiatr disord affect global
deuter d-serin potenti allevi effect schizophrenia without damag kidney
balu nmda receptor schizophrenia pathophysiolog treatment adv pharmacol pp
concert develop phase treatment schizophrenia
unlik concert program d-serin previous approv
drug previou independ clinic studi demonstr strong evid
safeti efficaci approach
deuter form d-serin natur occur amino acid
nmda receptor agonist
novel mechan action may prove allevi neg
symptom toler side-effect profil compar current
approv drug would first-in-class diseas
clinic studi could find
d-serin spoke
investig translat
credit program
higher averag po
phase
phase program includ crossov comparison d-serin singl multiple-ascend dose trial
expect enrol healthi volunt
concert initi phase studi evalu safeti toler pk singl oral dose healthi volunt
vs d-serin
concert initi phase single-ascend dose trial jan
initi phase data expect top-lin data expect
mechan action nmda receptor hypofunct hypothesi
nmda receptor
n-methyl-d-aspart nmda receptor glutamaterg
glutamate-bind receptor ion channel protein found
receptor ligand-g ion-channel activ
bind two ligand glutam either d-serin glycin
upon activ receptor magnesium ion
longer block ion channel calcium sodium
ion abl enter neuron potassium ion
pump
trigger downstream cascad event mediat
synapt plastic neurochem function relat learn
schizophrenia evid shown decreas nmda
receptor activ well decreas level d-serin
decreas serin racemas enzym respons convert
l-serin
balu nmda receptor schizophrenia pathophysiolog treatment advanc pharmacolog pp
mechan action nmda receptor hypofunct hypothesi
role nmda receptor schizophrenia
nmda receptor hypofunct propos mechan behind neg cognit
evid first propos treatment nmda receptor antagonist includ phencyclidin
ketamin adult produc syndrom indistinguish
preclin clinic studi suggest administr d-serin may benefici effect
treatment
clinic evid support use d-serin treatment schizophrenia
studi clinic
schizophrenia
trial healthi
adult assess
d-serin
use
intervent
reduct
dose rang
mg/kg
balu et al nmda receptor glycin modulatori site schizophrenia d-serin glycin beyond current opinion pharmacolog pp
krystal et al subanesthet effect noncompetit nmda antagonist ketamin human psychotomimet perceptu cognit neuroendocrin respons archiv gener psychiatri
kantrowitz high dose d-serin treatment schizophrenia schizophrenia research pp
clinic evid d-serin treatment schizophrenia
date investig initi clinic trial use d-serin human
studi investig use d-serin treatment schizophrenia studi assess
pharmacokinet healthi volunt
dose d-serin use vari mg/kg mg/kg
studi investig d-serin treatment found statist signific
improv endpoint use assess schizophrenia symptom
d-serin gener well-toler advers event minim advers event due abnorm kidney
function toxic minim
studi small size rang particip
deem necessari particip schizophrenia allow remain current anti-psychot
trial
studi differ inclusion/exclus criteria differ endpoint make comparison
studi difficult
detail evid efficacy/safeti d-serin treatment schizophrenia
d-serin daili
panss posit d-serin decreas baselin
week signific placebo
panss cognit d-serin decreas baselin
week signific placebo
san neg symptom d-serin decreas
baselin week signific placebo
side-effect similar
placebo d-
panss posit signific differ d-
serin placebo
panss cognit signific differ d-
serin placebo
wisconsin card sort test signific differ
d-serin placebo
panss posit d-serin decreas baselin
week signific placebo
panss cognit d-serin decreas
baselin week signific placebo
san d-serin decreas baselin
week signific placebo
unchang within
d-serin treatment well
toler signific
clinic lab
unaffect
d-serin daili
initi
risperidon
studi demonstr statsig effect d-serin across dose rang mg/kg
detail evid efficacy/safeti d-serin treatment schizophrenia
placebo d-serin
panss total signific differ d-
serin placebo
signific differ d-serin
placebo
signific differ d-serin
placebo
similar across treatment
group short-liv
requir medic treatment
dropout due advers
dose d-serin
d-serin well toler without
prior administr
consist
placebo sarcosin d-
panss total d-serin decreas baselin
signific placebo
san d-serin decreas
signific compar placebo
minim differ
mild
differ group
gener well toler across studi note patient withdrew due renal toxic patient
withdrew due proteinuria result believ see posit safeti profil phi
detail evid efficacy/safeti d-serin treatment schizophrenia
studi perform dose phase
subject receiv open-
clozapin
panss posit mg/kg dose decreas
baselin week signific
month washout period
exist
mg/kg trial
panss neg mg/kg dose decreas
baselin week signific
panss gener mg/kg dose mg/kg
significantli decreas score
panss total dose d-serin significantli
decreas score
treatment either placebo d-
high risk
sop total score d-serin group final score
compar placebo signific
sop neg score d-serin final score
compar placebo signific
sop posit score d-serin final score
compar placebo signific
report
mg/kg
dose
increas
proteinuria
resolv
treatment
arm suicid
thought week
remain
studi
due psychosi
d-serin
due renal
detail evid efficacy/safeti d-serin treatment schizophrenia
measur brain respons
stimulu record eeg
chang detect time
deviant tone play within
part sequenc eeg
measur respons
auditori stimuli brain
safeti
assess
patient
permit receiv
anticholinerg
event-rel potenti erp /time-frequ
signific differ notic placebo d-
serin initi treatment day dose d-
serin consecut result signific
signific differ d-serin vs placebo
one session signific differ
d-serin schizophren control
patient receiv consecut dose d-serin
signific differ respons train
tone vs placebo group chang mmn
correl signific
tsai et al d-serin ad antipsychot treatment schizophrenia biol psych pp
tasi et al d-serin ad clozapin treatment schizophrenia psych pp
heresco-levi et al d-serin efficaci add-on pharmacotherapi risperidon olanzapin treatment-refractori schizophrenia biol psych pp
lane h-i et al sarcosin d-serin add-on treatment acut exacerb schizophrenia gen psych pp
tsai et al disposit d-serin healthi adult clin pharmacol pp
lane h-i et al random double-blind placebo-control comparison studi sarcosin n-methylglycin d-serin add-on treatment schizophrenia neuropsychopharmacol pp
kantrowitz et al high dose d-serin treatment schizophrenia schizophrenia research pp
kantrowitz et al d-serin treatment neg symptom individu clinic high risk schizophrenia proof-of-concept trial lancet psych pp
kantrowitz et al neurophysiolog mechan cortic plastic impair schizophrenia modul nmda receptor agonist d-serin brain pp
vitro vivo studi concert compar characterist deuter d-serin d-serin
data present act annual meet west palm beach fl nov
nmda receptor activ detect use
human embryon kidney cell express
receptor patch-clamp system
measur activ
differ d-serin term
nmda receptor activ
rat dose oral shown iv
d-serin
greater half-lif auc cmax
similar tmax report bioavail
slightli less
rat dose oral mg/kg
brain tissu plasma harvest
hour exposur
accumul rat forebrain
data releas compar tissu
distribut d-serin
safeti profil focu nephrotox
one concern develop drug evid nephrotox occur rat
studi inject male sprague-dawley rat intraperiton low dose high dose d-serin
low dose mg d-serin per bodi weight high dose mg per bodi weight
low-dos group inner renal cortex proxim straight tubul kidney appear necrot
hour post treatment hour proxim straight tubul appear
necrot contrarili rat treat l-serin exhibit symptom
high-dos group evid nephrotox began appear hour hour necrosi
inner cortex proxim straight tubul observ cell within proxim straight tubul
necrot
high-dos group rat sacrif day post treatment proxim straight tubul complet
relin epithelium studi note anim die due treatment
thing consid studi use high dose d-serin rel mass comparison dose use
human studi dose use excess
human studi nephrotox commonli report advers event
ganot et al natur d-serine-induc nephrotox american journal patholog pp
safeti profil focu nephrotox
compar safeti profil d-serin concert treat rat increas dose either compound vehicl
use control rat dose oral mg/kg increment start mg/kg
toxic assess measur level blood urea nitrogen bun creatinin present serum
rat dose d-serin mg/kg bun creatinin level normal
rat group elev level creatinin given mg/kg dose
marker
dose depend
stay within
rat dose
mg/kg
dash line repres upper level
normal rang blood urea nitrogen
dash line repres upper level
normal rang creatinin
schizophrenia chronic psychiatr disord affect global
diseas manifest sex slightli preval men ethnic
commonli present adolesc earli adulthood
diseas herit increas risk
diseas heterogen one gene
identifi sole caus diseas
environment factor rais
contribut develop
diseas diagnos base
symptom must present
american psychiatr associ diagnost statist manual mental disord
schizophrenia character classif symptom
speech anhedonia
current lab test biomark definit diagnos schizophrenia
diseas must properli diagnos psychiatrist base sever symptom commonli associ diseas
criteria identifi diagnost statist manual mental disord edit dsm-v
symptom must present least month least symptom must includ delus hallucin disorgan speech
perform work interperson relat self-car impair
symptom disord last continu period least month
exclus mood disord
rule psycholog disord includ schizoaffect disord bipolar disord
exclus substanc medic condit
rule medic anoth diseas caus symptom
relationship commun disord
alreadi diagnosi autism addit diagnosi schizophrenia ad delus hallucin occur least month
best known antipsychot treatment schizophrenia involv correct increas dopaminerg
dopamin receptor antagon gener properti approv anti-psychot
current specif biomark may use select effect
respons treatment highli variabl usual efficaci seen within first week
patient respond within week recommend switch medic differ mechan action
first episod psychosi treatment recommend year
multi-episod patient recommend continu treatment least year
failur respond differ antipsychot classifi patient treatment resist
patient treatment resist
clozapin drug proven efficaci group patient
major antipsychot benefit posit
current antipsychot littl effect neg symptom often regard detriment posit symptom
neg symptom blame much person econom cost diseas
patient schizophrenia show sign persist neg symptom
major antipsychot harsh side-effect
kahn et al neurobiolog treatment first-episod schizophrenia molecular psychiatri pp
lalli et al antipsychot medic schizophrenia review british medic bulletin pp
sarkar et al conceptu treatment neg symptom schizophrenia world journal psychiatri pp
limit current anti-psychot therapi
current anti-psychot drug abl allevi posit symptom hallucin delus mani patient howev manag
neg symptom cognit deficit remain unmet medic
vast major drug approv schizophrenia similar mechan action thu similar clinic effect side-effect
talpo symptomat think current state phase iv clinic trial cognit schizophrenia drug discoveri today pp
common approv schizophrenia
summari competit landscap schizophrenia
anti-psychot pipelin schizophrenia treatment
sever drug develop treatment schizophrenia
mani drug target novel pathway dopamin serotonin receptor
goal target new pathway vari new therapeut intend allevi neg and/or cognit
symptom prevent relaps psychosi serv treatment anti-psychot fail
glycin transport type inhibitor muscarin acetylcholin machr receptor agonist
nmda receptor agonist uniqu target amongst competit
mention kol unlik treatment fit everyon schizophrenia individu symptom
profil thu room market one treatment especi abl effect
neg cognit symptom associ diseas
competit landscap schizophrenia
anti-psychot pipelin schizophrenia treatment
target posit neg cognit
symptom relaps inadequ
competit landscap schizophrenia contd
anti-psychot pipelin schizophrenia treatment
target posit neg cognit
competit landscap schizophrenia contd
anti-psychot pipelin schizophrenia treatment
target posit neg cognit
market opportun treat individu us
incid preval us global
within diagnost criteria dsm-v schizophrenia global lifetim incid preval peopl per
accord nation institut mental health preval schizophrenia relat psychot disord us rang
similar global
given current us popul estim popul schizophrenia assum preval
patient elig
view drug possibl adjunct therapi current anti-psychot may abl address neg cognit symptom diseas
patient schizophrenia persist neg
estim us schizophrenia patient consist neg symptom assum preval
anoth patient popul limit pharmaceut strategi treatment-resist mean fail
respond least anti-psychot therapi fail respond clozapin anoth discontinu use due
base averag drug price recent launch anti-psychot abilifi aripiprazol rexulti brexpiprazol latuda lurasidon estim ctp-
annual cost exclud aristada due differ administr profil monthli inject
schizophrenia chronic diseas estim patient receiv therapi regular basi
model sale ramp recent drug launch anti-psychot list estim peak sale occur year drug launch
assum annual drug price target popul total market opportun patient neg symptom
estim peak us sale adjust base po
lalli et al treatment resist schizophrenia review call action irish journal psycholog medicin pp
sarkar et al conceptu treatment neg symptom schizophrenia world journal psychiatri pp
recent product launch antipsychot
drug sale antipsychot potenti reach blockbust statu
sale estim occur year post-launch
total ww market valu top product
assist professor
phd pharmacolog
research focus
mechan caus
may
pre-
nmda receptor hypofunct hypothesi
hypothesi evid sever differ avenu pharmacolog healthi
volunt given ketamin pcp present hallucin alter
cognit schizophren patient genet find point alter glutamaterg
transmiss rare variant mutat gene occur schizophren patient
control neurochem differ post-mortem brain tissu lower level d-serin
awar hypothesi
establish research tend buy wouldnt say controversi
current avail antipsychot medic work posit symptom neg
cognit symptom well manag current
therapi work
dopaminerg action physician know drug suffici believ physician
awar
nephrotox rodent studi
long-term studi d-serin serin racemas knockout ko model
intraperiton oral dose sent kidney patholog didnt notic kidney
problem week give dose got back normal level literatur
nephrotox rat studi super high dose didnt see anyth mice
concert preclin data
compar vs d-serin human embryon kidney cell look look patchclamp
physiolog say compound perform well induc nmda receptor current that good that
want complet might want see brain slice physiolog rodent brain endogen express
nmda receptor whether compound perform well better d-serin regul nmda receptor
dose rat oral compound higher half-lif good look plasma concentr
gave rat singl dose look hour later look distribut across tissu main site action
forebrain see nice amount enrich forebrain brainstem cerebellum lower d-amino
acid oxidas break d-serin enrich hindbrain make sens would nice compar
d-serin compar blood-brain barrier permeabl
dose
clinic trial recruit look auditori plastic patient schizophrenia alter auditori
function exampl studi dose mg/kg concert mg/kg poster ballpark
peopl done propos use schizophrenia concert side side metabol show
side side brain accumul could show could use less deuter vs regular d-serin
d-serin therapi would fit within exist anti-psychot treatment landscap
there monotherapi potenti stand-alone might need stabil
antipsychot taper base concert websit seem like think adjunct therapi well
literatur show agonist dont work well patient clozapin could adjunct long clozapin
would much safer adjunct therapi probabl safer bet first
think potenti monotherapi also depend stage diseas patient earli onset
patient schizophren year brain quit differ d-serin might effect catch patient earli
one studi look patient clinic high risk teenag receiv d-serin small patient popul
show improv neg symptom patient
ideal clinic trial design would phase ii
would look adjunct therapi clozapin placebo control doubl blind would ideal
phase ii small sampl size dont know picki stratif patient earli diseas process
would nice
durat usual need wait week see effect least week drug work im sure follow
think prolong half life look like potenti fewer kidney function assum get
brain least good regular d-serin enhanc nmda receptor function least well d-serin think itd good
psychiatrist assist
schizophrenia
well
nmda receptor hypofunct hypothesi
nmda theori expand glutaminerg theori nmda common activ
receptor brain research focus nmda receptor base chanc bond
ketamin drug block receptor pretti activ simul symptom
schizophrenia peopl appear diseas min long drug activ
group tri use drug activ receptor number
differ site activ cant use glutam would overstimul brain
co-sit like d-serin d-serin doesnt activ activ receptor co-agonist
presenc glutam
awar hypothesi
probabl like psychiatrist least heard glutaminerg theori
schizophrenia probabl well vers dont glutaminerg treatment
enthusiasm within medic commun antipsychot new moa
think base anecdot dopamin anti-psychot market littl
flood howev someth work differ affect posit neg
symptom would excit current treatment
patient would benefit d-serin therapi
would say unlik well ever find one treatment work everyon schizophrenia probabl differ ill
said probabl good portion schizophren would respond medic like d-serin
type peopl would respond would like cognit deficit neg symptom roughli
like patient respond d-serin sicker group patient state hospit patient wind residenti care
wouldnt rule gener out-pati respond littl less like glutaminerg deficit patient tend sicker end
residenti set
greatest limit affect everybodi effect posit neg symptom side effect
greatest limit antipsychot
prefer treatment schizophrenia
peopl use antipsychot olanzapin risperidon realli treat symptom better other use
moder sever tend tri someth less weight gain first like aripiprazol work pretti well less weight gain
liabil also use lot olanzapin despit weight gain liabil
dose d-serin use clinic trial
d-serin studi im familiar success except largest fail strong thought
use low dose dose need especi pill form complic use need higher dose
studi studi colleagu use higher dose current project tri push mg/kg
concern publish trial higher person proteinuria week
treatment rel mild decid pursu sinc seem work well
use d-serin add-on therapi
work use add-on treatment fund id love stand-alone treatment think there
strong chanc would work far know one studi like publish colleagu involv conduct
israel rel treatment resist patient high dose olanzapin vs d-serin open label studi seem work reason well
prefer anti-psychot add-on therapi
definit possibl reduc antipsychot base evid one particular medic would use
use clozapin dont particular prefer clozapin probabl work glutam agonist
also number studi show nmda agonist drug didnt work clozapin
nephrotoxcitiy seen d-serin
per nda fda allow move forward escal dose think worth pursu dont know
nephrotox real dont expect find ae
clinic trial design phase ii studi
dont think need particularli larg charg id start small scale biomark studi keep limit
number site know depend mani dose possibl patient would find id probabl
includ regular serin option control id keep primari outcom biomark mismatch neg
treat patient approv
absolut your ask true believ would tri everybodi
probabl add first saw well done monotherapi studi suspect good chanc work without
studi wouldnt know sure
schizophrenia revenu assumpt sale po
understand street gener alloc valu program believ higher averag phase po due
effect nmdar dysfunct underli neuroplast deficit neuroplast enhanc effect seen repeat d-serin use
epidemiolog estim preval base definit
target patient popul take lower end patient schizophrenia persist deficit neg symptom
may addit elig patient fail treatment clozapin discontinu use due howev includ model
sale review sale ramp approv antipsychot model long sale ramp base primarili abilifi latuda
conserv model doesnt achiev peak sale base case includ termin valu growth
price base averag drug price data recent launch anti-psychot focu abilifi price assum chronic therapi
complianc kol experi principal/co-investig author sever nimh-fund multicent trial glutam base
treatment includ first demonstr efficaci high dose d-serin estim d-serin effect patient
sourc sarkar et al conceptu treatment neg symptom schizophrenia world psychiatr
revenu us popul patient total schizophrenia patient neg symptom schizophrenia patient neg patient penetr cost therapi increas us sale adjust us net sale compani report lifesci capit estim march
alzheim agit
concert partner program avanir alzheim agit
deuter formul dextromethorphan combin low-dos quinidin
treatment alzheim agit
concert grant otsuka/avanir exclus world-wide licens develop
manufactur commerci deudextromethorphan deuterated-dextromethorphan drug product
fda approv treatment alzheim agit avanir nuedexta combin pill mg
dextromethorphan dm mg quinidin often use off-label treat condit
deuter dextromethorphan increas bioavail decreas amount quinidin
inhibitor necessari pill slow-down first-pass liver metabol
phase trial progress us
top-line data expect studi
trial complet expect support nda file
million american alzheim
agit
preval agit high moderate-sever ad
conserv patient treat agit roughli million peopl
halpern et al use electron health record estim preval agit alzheim disease/dementia intern journal geriatr psychiatri pp
et medic develop agit aggress alzheim diseas review discuss recent random clinic trial design intern psychogeriatr pp
deal avanir pharmaceut
februari concert enter develop licens agreement grant avanir exclus
world-wide licens develop manufactur commerci deuter dextromethorphan product
sinc june avanir conduct research develop activ includ manufactur
concert receiv reimburs intellectu properti
concert receiv non-refund payment receiv mileston payment
payment due respect licens product contain deuter dextromethorphan quinidin
concert elig earn regulatori commerci launch mileston payment
tie develop mileston payment first indic alzheim agit
compani agreement receiv sales-bas mileston payment
all-in equat concert launch success
acquir
mg dextromethorphan hbr mg quinidin sulfat
approv drug indic
increas gamma-glutamyltransferas flatul
licens avanir
deuter ultra-low dose quinidin
peopl ad us requir treatment
agit total market estim patient popul
fda approv drug indic
phase ii/iii develop alzheim agit
expect less compar nuedexta due
lower-dos quinidin use drug
agit common neuropsychiatr symptom associ alzheim diseas agit often complex
occur frequent may becom problemat patient famili member caregiv
agit lack specif univers definit emot distress restless aggress uncoop behavior disrupt
irrit associ
formal intern psychogeriatr associ broadli defin agit cognit disord
occur patient cognit impair dementia
behavior perceiv emot distress
behavior attribut anoth underli caus psychiatr medic substanc abuse/misus
neurobiolog behind caus diseas well understood certain symptom associ chang
agit aggress associ brain chang frontal limbic region includ amygdala
agit fidget pace link increas neurofibrillari tangl nft orbitofront cortex area brain involv
increas nft hippocampu tie increas sever aggress behavior
alter neurotransmitt includ serotonin glutam
porsteinsson et al updat advanc treatment agit alzheim diseas expert opinion pharmacotherapi pp
van dam et al neuropsychiatr disturb alzheim diseas learn neuropatholog studi current alzheim research pp
antonsdottir et al advanc treatment agit alzheim diseas expert opinion pharmacotherapi pp
current treatment alzheim agit
approv therapi alzheim agit sever drug use off-label treat condit
behavior intervent fail allevi symptom pharmacolog approach warrant
kol insight around alzheim patient requir pharmacolog treatment agit
fda issu public health advisori treat behavior disturb dementia atyp
antipsychot data placebo control trial report increas risk death
risperidon olanzapin aripiprazol offer benefit use limit due advers event
movement disord sedat increas risk fall cognit declin cardiovascular event mortal
citalopram studi notabl rct patient receiv mg daili placebo week
neurobehavior rate scale agit subscal nbrs-a particip citalopram
signific differ compar placebo
cohen-mansfield agit inventori cmai citalopram associ improv score
compar placebo signific differ
howev studi author note high dose mg/day may limit use citalopram due
cognit cardiac relat advers event
gallagh et al agit aggress alzheim diseas updat pharmacolog psychosoci approach care neurodegen diseas manag pp
porsteinsson et al effect citalopram agit alzheim diseas citad random control trial journal american medic associ pp
continu next slide
current treatment alzheim agit contd
blackbox warn use antipsychot dementia patient
sinc typic atyp antipsychot come black-box warn issu fda warn
state treatment behavior disord antipsychot medic elderli patient dementia
associ increas mortal
april fda announc requir black-box warn label atyp antipsychot state dementia patient
higher risk death follow retrospect studi new england journal medicin identifi
typic atyp antipsychot like increas risk death patient
june fda extend black-box warn includ typic antipsychot result off-label use antipsychot treat
elderli patient dementia declin slightli one studi elderli outpati dementia report declin patient
take antipsychot psychotrop black-box warn
wang et al risk death elderli user convent vs atyp antipsychot medic new england journal medicin pp
yan fda extend black-box warn antipsychot psychiatr news american psychiatr associ
desai et al impact food drug administr antipsychot black box warn psychotrop drug prescrib elderli patient dementia outpati office-bas set alzheim dementia
continu next slide
current treatment alzheim agit contd
approv therapi alzheim agit sever drug use off-label treat condit
dextromethorphan uncompetit nmda receptor antagonist receptor agonist inhibitor
serotonin norepinephrin transport quinidin inhibitor
dm/q formul mg dextromethorphan mg quinidin current market nuedexta
approv treatment pseudobulbar affect condit occur peopl neurolog
condit character episod uncontrol laugh cri often inappropri time
studi suggest chang glutamaterg signal ad may play role cognit behavior
chang seen nmda receptor antagonist dextromethorphan may benefici treatment
alzheim agit sinc excess nmda receptor signal caus neuron excitotox
quinidin known inhibitor dose combin dextromethorphan abl suppress
format first-pass metabolit dextrorphan dextromethorphan quinidin abl increas
bioavail half-lif dextromethorphan allow drug remain activ
franci glutamaterg approach treatment cognit behaviour symptom alzheim diseas neuro-degen diseeas pp
wang et al role glutam nmda receptor alzheim diseas journal alzheim diseas pp
schadel et al pharmacokinet dextromethorphan metabolit human influenc phenotyp quinidin inhibit
clinic evid dm/q treatment alzheim agit
phase ii rct studi fund nuedexta dm/q assess safeti toler efficaci
treatment alzheim
sequenti parallel comparison trial design stage patient age probabl ad random
receiv dm/q placebo week dm/q dose titrat mg daili
week twice daili week increas mg twice daili week stage particip
receiv dm/q continu receiv placebo separ respons re-random receiv dm/q
placebo
particip complet studi receiv dm/q receiv placebo
primari endpoint chang baselin stage combin assess neuropsychiatr inventori
npi agitation/aggress domain score dm/q significantli lower score vs placebo
advers event dm/q vs placebo includ fall vs diarrhea vs uti vs
dm/q associ cognit impair sedat signific qtc prolong overal well toler
cum et al effect dextromethorphan-quinidin agit patient alzheim diseas dementia journal american medic associ pp
develop combin treatment deuter dextromethorphan low-dos quinidin
treatment alzheim agit avanir receiv track design fda indic
deuter form dextromethorphan allow better pharmacokinet
bioavail slow first-pass metabol liver enzym
quinidin well-character inhibitor also use
antiarrhythm agent monotherapi start dose mg indic
treatment atrial fibril afib drug caus increas action potenti
durat also prolong qt interv nuedexta addit quinidin
far less start dose afib still concern among
prescrib accord kol give small amount quinidin
alzheim patient lowest amount possibl prefer quinidin may
also lead drug-drug interact sinc drug may requir degrad
order metabol appropri
deuter dextromethorphan improv bioavail allow
combin drug low-dos quinidin could improv safeti
profil compar nuedexta well limit drug-drug interact
garay et al treatment agit dementia alzheim type expert opinion investig
complet phase clinic studi current phase trial us global
februari avanir announc posit interim data complet phase rct studi assess pk safeti toler avp-
comparison nuedexta healthi volunt
avanir releas data report replic steady-st plasma level nuedexta lower-
dose quinidin
complet four phase studi healthi volunt assess pk safeti toler drug-drug interact anti-
depress paroxetin duloxetin antifung
june fda agre expedit develop pathway grant avanir abil refer data gener
clinic trial nuedexta support
nov avanir began phase studi studi design evalu efficaci safeti
toler dose ad particip agit studi multicent random double-blind
primari endpoint includ chang baselin week cohen mansfield agit inventori cmai score
secondari endpoint includ neuropsychiatri inventori npi agitation/aggress domain npi domain measur global
clinic chang measur caregiv burden well qualiti life
expect enrol center us expect enrol approxim patient center us
phase enrol slow unusu accord kol
top-lin data expect read
avanir initi sever phase ii studi us indic includ neurobehavior disinhibit schizophrenia
press releas avanir pharmaceut announc acceler develop path follow success pre-ind meet fda
press releas avanir pharmaceut announc initi phase trial agit patient alzheim diseas
competit landscap alzheim agit
competit alzheim agit market bioxcel also combin
drug dextromethorphan anoth inhibitor bupropion bupropion monotherapi act atyp antidepress
kol prefer low-dos quinidin bupropion inhibitor sinc bupropion may high enough dose
exert antidepress effect
low-dos
antagonist inhibitor serotonin norepinephrin transport
sublingu film
bupropion
antagonist inhibitor serotonin norepinephrin transport
bupropion norepinephrin dopamin reuptak inhibitor nicotin
press releas track design help facilit anticip registr trial upon complet pharmacokinet
bioavail safeti studi
evalu pharma press releas dec provid year end clinic updat
signific multi-billion dollar market opportun
preval alzheim diseas us global
global estim preval alzheim diseas
estim us
estim patient popul elig drug
ad patient agit
current approv therapi indic sever drug use off-label make definit estim patient receiv
treatment difficult find
kol provid conserv estim alzheim patient receiv pharmacolog treatment agit
estim patient popul elig million peopl us
drug price estim averag nuedexta nuplazid
price nuedexta dextromethorphan/quinidin chronic treatment would howev agit treatment episod
acadia pharma nuplazid pimavanserin launch treatment parkinson diseas psychosi pdp nuplazid
treat symptom respect diseas neither approv drug
estim across us canada pd pdp
nuplazid achiev sale impli market penetr second year post-launch market penetr
estim would equat would
accord kol potenti use market remaind patient treat ssri antipsychot
optimist perspect repres upsid potenti model base case penetr
estim us peak sale adjust base po po adjust believ concert achiev
maximum royalti payment
halpern et al use electron health record estim preval agit alzheim disease/dementia intern journal geriatr psychiatri pp
soto et medic develop agit aggress alzheim diseas review discuss recent random clinic trial design intern psychogeriatr pp
professor psychiatri
qualif geriatr
alzheim diseas
agent treatment
co-author hundr
research public
kol experi alzheim patient
train psychiatrist geriatr psychiatri focu care treatment peopl
memori diseas time clinic care two-third time clinic research earli
symptomat alzheim diseas alway major research focu behavior disrupt
particular agit focu agit particular look
mood-stabil anti-convuls trial design trial execut number paper focu
atyp antipsychot citalopram escitalopram involv pimavanserin
definit alzheim agit
intern psychogeriatr associ ipa definit provision criteria alzheim
agit diagnost criteria blend togeth criteria often combin want agit
certain pattern behavior present least week creat disrupt peopl live
due medic
ill anoth psychiatr condit affect medic
someth come
opposit behavior uncoop verbal abus physic abus time
behavior troublesom enough creat disabl
preval alzheim agit
agit quit common one common behavior disrupt there rang
roughli defin agit peopl agit need treatment
current treatment agit
depend symptom focus use ssri citalopram escitalopram sad anxieti know
respond ssri treatment well inabl modifi mood agit may move toward dextromethorphan/quinidin
nuedexta mood control see paranoia
intens hostil aggress lean toward
antipsychot shown consist benefici group hostil lean toward
antipsychot sleep disrupt may tri melatonin sleep modul patient sleep better caregiv get
better rest abl deal plate
wont dramat chang pictur posit data releas support use escitalopram agit
approv treatment your treat peopl off-label vari state due reimburs
use dextromethorphan/quinidin nuedexta treatment alzheim agit
never realli uncomfort origin nuedexta quinidin often highlight drug inhibit metabol
medic affect cardiac rhythm quinidin use antiarrhythm dose higher peopl rais
concern nuedexta dose lower babi dose comfort peopl degre quinidin dose
mg probabl make peopl reason comfort dose quinidin pretti darn miniscul
like quinidin better bupropion refer dextromethorphan/bupropion combin pill develop
axsom mg quinidin vs mg bupropion kind clinic activ dose
bupropion may use depress agit dose quinidin inconsequenti
may use ssri there move look dm/q dextromethorphan/quinidin treatment mood disord
inabl modul mood disord lean toward dm/q irrit may lean toward ssri
use dextromethorphan/quinidin
definit fair amount off-label use fair amount agit symptom pseudobulbar affect doctor use dm/q today
agit get approv insur compani compound
dm/q pretti easi use side-effect profil pretti manag first impress prescrib quickli take effect
work patient stay look use pba pseudobulbar affect often use pba doesnt go
away neither agit use fairli persist measur sever month
current clinic trial
took long time recruit add site opinion base experi use dm/q off-label feel dm/q
work work peopl agitationrecruit agit trial like swim molass dont move fast
futur approv
fda approv medic big effect assum peopl agit
need treatment could receiv drug approv
youll sens patient dm/q work best ssri depend prescrib experi
medic one thing advantag dm/q ssri work quickli wherea dm/q see separ placebo
within week hold true strong market point gener experi
thing biggest benefit right prescrib nuedexta insur compani bound hound prior
author invari get denial agit hassl factor decreas that realli there indic
insur compani cant come back anyth thing matter pcp usual prescrib med want go
step step prescript learn reach someth els easier handl
alzheim agit revenu assumpt sale po
epidemiolog take lower end estim patient alzheim diseas demonstr agitation/aggress per kol
lead larg center focus alzheim diseas care origin author avanir phase ii trial nuedexta
target patient popul kol estim ad patient agit need treat current ssri atyp antipsychot
sale estim potenti launch could occur given track design howev time depend otsuka/avanir
price averag annual cost therapi sale ramp nuplazid parkinson diseas psychosi nuedexta pseudobulbar
royalti interpret potenti royalti concert cap limit potenti royalti revenu program
mileston separ assum concert achiev regulatori launch mileston first indic
begin phase readout also po
revenu alzheim ad patient total patient agitation/aggress patient diagnos treatment patient patient penetr cost therapi increas us sale adjust us net sale royalti royalti concert exclud adjust royalti compani report lifesci capit estim march
addit asset non dilut fund
acquisit vertex
vertex acquir concert march concert receiv up-front cash elig receiv
mileston base regulatori approv appli po
deuter version ivacaftor ivacaftor market vertex tradenam kalydeco treatment cystic fibrosi
patient specif mutat cftr gene
ivacaftor current dose one mg tablet taken bid vertex plan initi dose-rang phase ii studi examin potenti
once-daili therapi
concert publish preclin vivo data compar vs ivacaftor data provid clear evid deuter chang
pharmacokinet cmax auc parent
phase clinic data
concert present phase data healthi volunt singl dose
comparison mg tablet vs kalydeco volunt given
tablet drug day crossov trial design volunt
given altern drug dose schedul follow wash-
period
figur show increas vs kalydeco
mean half-lif also increas kalydeco hr vs hr
deuter improv pk profil kalydeco potenti
daili version kalydeco instead recommend
bid schedul non-deuter ivacaftor
harbeson et al alter metabol profil drug precis deuter discoveri
deuter analog ivacaftor differenti pharmacokinet clinic develop journal pharmacolog
experiment therapeut pp
concert tablet confirm superior pharmacokinet profil rel kalydeco phase clinic
partnership celgen
concert strateg collabor celgen develop inflammatori diseas may
concert receiv up-front payment celgen elig earn develop mileston
regulatori mileston sales-bas mileston payment first indic
deuter version apremilast select inhibitor phosphodiesters pde enzym celgen
celg market apremilast tradenam otezla treatment psoriasi activ psoriat arthriti
apremilast current dose mg twice daili follow titrat period start drug
phase single-ascend dose multiple-ascend dose studi complet concert
daili dose mg administ healthi volunt steady-st exposur
compar histor data twice daili dose mg apremilast healthi volunt find similar
concert also report gener well-toler sae observ
move forward celgen respons develop beyond complet phase clinic trial
current clinic trial regist clinicaltri gov
comment celgen concert potenti acquisit announc jan celgen bristol-my squibb
nyse affect futur program
model ascrib valu program potenti futur mileston
deuter sodium oxyb pharmaceut
concert hold ip regard composit matter deuter analog sodium oxyb d-sxb well
method use concert grant exclus patent right regard program
up-front payment develop mileston regulatori
mileston sales-bas mileston payment next anticip mileston payment relat
phase ii initi d-sxb compound
d-sxb deuter class analog sodium oxyb sodium oxyb current market tradenam xyrem
sodium oxyb depress current indic treatment narcolepsi patent expiri date
xyrem
concert complet phase single-ascend dose studi phase studi demonstr favor effect
pharmacodynam compar xyrem decid advanc program
current activ clinic trial program regard d-sxb analog
model ascrib valu program potenti futur mileston
acquir processa pharmaceut
previous develop concert treatment diabet kidney diseas concert
grant processa over-the-counter pcsa exclus royalty-bear licens develop commerci manufactur ctp-
concert receiv share common stock processa fair market valu
previou agreement glaxosmithklin nyse gsk regard develop concert receiv
payment gsk opt develop concert oblig make payment gsk
receiv cash proce re-licens
deuterated-analog hdx hdx activ metabolit
drug pentoxifyllin approv treatment chronic occlus arteri diseas extrem
achiev primari end-point phase ii trial particip diabet kidney diseas
primari end-point chang baselin week urinari albumin creatinin ratio uacr measur
kidney tissu damag dose mg bid placebo given total particip complet
portion studi
gener well toler mild moder nausea report common treatment relat ae
sae occur none link studi drug
processa current develop treatment necrobiosi lipoidica necrot skin condit occur
comorbid diabet mellitu current phase ii open-label trial top-lin data anticip
cipla develop spastic
previous develop concert compani recent announc licens
develop indic nse cipla concert receiv up-front
cipla potenti receiv mileston royalti payment concert exist agreement place
non-profit organ forward regard owe half up-front payment
forward also oblig make modest mileston payment forward
deuter analog molecul known previous discov merck nyse
select gabaa posit alloster modul behav similarli benzodiazepin class drug
concert develop treatment spastic patient spinal cord injuri multipl sclerosi
complet phase clinic trial advers effect report three-month toxicolog studi non-
clinic model march concert receiv partial clinic hold letter fda regard decid
advanc program
cipla receiv exclus world-wid licens develop commerci investor present
intend develop compound treatment spastic movement disord
model appli up-front payment assum payment forward period
valu given potenti mileston
compani earn call
concert extens ip portfolio encompass patent issu patent trademark offic uspto nearli
patent relat applic concert dce-platform technolog non-deuter drug drug candid
addit patent issu ex-u ip relat clinic pipelin outlin
deuter ruxolitinib alopecia areata
cover us patent
patent cover sever deuter analog ruxolitinib
concert hold us patent applic cover composit matter method use patent issu
anticip expir concert hold patent right
concert hold us patent pend us patent applic cover composit matter method use deuter
dextromethorphan analog
patent patent applic approv expect expir
patent right grant exclus licens avanir
concert hold two us patent us patent applic cover composit matter deuter sodium oxyb analog well
method use
us patent patent applic approv expect expir
concert hold european patent expect expir
concert grant exclus licens patent right
deuter analog inhibitor apremilast
concert hold us patent cover composit matter method use regard patent expect expir
concert grant exclus licens celgen patent right
inter part review ipr
ipr decis confirm april point expect stock face neg pressur short term
inter part review decis matter expect april
ruxolitinib patent market tradenam jakafi incyt corpor
ruxolitinib cover us patent
file ipr petit concert seek invalid patent patent trial appeal board ptab origin deni
petit accept motion reconsider decis ipr petit expect april
win petit could sever affect concert abil develop market commerci
inter part review ipr establish procedur challeng valid patent
ipr use challeng patent claim ground rais
base ground anticip prior literatur describ claim outlin patent
base ground obvious patent claim would obviou someon ordinari skill art
inter part review ipr contd
issu ipr petit invalid concert patent claim base
seek invalid claim us patent deuter deriv ruxolitinib
initi patent trial appeal board ptab side concert deni institut ipr basi
show reason likelihood prevail petit ground anticip obvious
howev ptab respond request rehear ground patent claim obviou base combin
prior refer
decis ipr expect april
timmin deuter drug updat obvious analysi expert opinion patent pp
kol insight ipr concert
spoke ip kol subject inter part review
outlook concert come rehear gave po posit outcom
atyp ptab consid rehear deni petit indic convinc new evid
main take-away call ptab reconsider realli except happen rarest set case given fact
ptab said deni agre reinstitut ptab eye cancel patent
concert still proceed clinic develop without patent elig year market exclus
date nda approv drug product contain new chemic entiti nce section feder food drug
year market exclus consol prize lose patent protect expir
per kol may still abl file lawsuit concert infring patent prepar manufactur market
may result court proceed settlement form one time up-front payment equival royalti
sale year
dcf model revenu build
dcf valuat year price share
dcf except per oper invest borrow -- -- -- -- -- -- fcfe present dcf summari dcf sensit price per sharesum fcfe rateless net equiti close price dilut share outstand growth dcf price per share discount ratefcftermin valueplatformdebtcash equiti lifesci capit compani reportsterminalgrowth march
catalyst rich year concert
ptab decis ipr challeng us patent
initi food-effect trial healthi volunt
vertex expect initi phase ii monotherapi trial
phase iia data readout third dose cohort mg
phase ii data readout mg qd vs mg bid studi
otsuka/avanir second phase trial decemb alzheim agit
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
